Navigation Links
Peramivir Protects Mice From Lethal H5N1 Infection

St. Jude study shows intramuscular injection of peramivir for eight days protected mice from lethal H5N1 influenza virus infection and inhibited virus replication, supporting the use of this drug to control influenza during a pandemic

MEMPHIS, Tenn., May 01, 2007 /PRNewswire-USNewswire/ -- The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.

Peramivir, an antiviral drug, blocks the ability of influenza viruses to use an enzyme called neuraminidase, thus preventing the release of new virus particles and their spread from one infected cell to another.

The researchers reported 100 percent survival among 10 infected mice given intramuscular injections of peramivir daily for eight days. The drug also inhibited the replication of the deadly strain of H5N1 virus in the lung, brain and spleen. The key to the high survival rate was treating the infected mice within 24 hours after infection with H5N1 and continuing the treatment for eight days.

"Peramivir should be given as soon as H5N1 infection is suspected, since onset of symptoms in infected humans can be delayed," said David A. Boltz, Ph.D., a postdoctoral fellow in the laboratory of Robert G. Webster in the Infectious Diseases department at St. Jude. "The drug could also be given as a preventive measure during an outbreak to decrease the risk of infection." Boltz is first author of a paper that was presented Mon., April 30 at the 20th International Conference on Antiviral Research in Palm Springs, Calif.

"We were surprised that we could also see a 40 percent survival rate among mice after just a single dose of peramivir," said Elena A. Govorkova, Ph.D., a scientific manager in the Infectious Diseases department at St. Jude. Govorkova is the paper's senior author.

"We are currently studying the emergence of H5N1 variants that are resistant to this drug and may occur in the course of treatment," said Natalia A. Ilyushina, Ph.D., a postdoctoral fellow in Webster's laboratory and a co- author of the paper.

Other authors of this report include Robert G. Webster (St. Jude) and C. Shane Arnold and Y. Sudhakar Babu (BioCryst Pharmaceuticals Inc., Birmingham, Ala.).

This study was supported by National Institute of Allergy and Infectious Diseases, the U.S. Public Health Service, BioCryst Pharmaceuticals and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit

CONTACT: Carrie Strehlau, Public Relations, +1-901-495-2295,, or Summer Freeman, Public Relations,+1-901-495-3061, , or Marc Kusinitz, Ph.D.,Scientific Communications, +1-901-495-5020, , allof St. Jude Children's Research Hospital

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights rese rved.
A United Business Media Company


Related medicine technology :

1. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
2. St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection
3. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
4. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
5. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
6. New Assays to Detect Disseminated Fungal Infections
7. Antibiotics Dont Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections
8. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
9. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
10. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
11. Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin in Complicated Urinary Tract Infections and Acute Pyelonephritis
Post Your Comments:
(Date:11/30/2015)... 30, 2015  PTS Diagnostics, the U.S.-based manufacturer of ... analyzers, A1CNow ® systems, and PTS Detect™ cotinine ... patents that will propel the company into the mHealth ... Europe . The technology is a system ... on smartphones and tablets, and uses test strip technology ...
(Date:11/30/2015)... NASHUA, N.H. , Nov. 30, 2015 /PRNewswire/ ... today that it will feature its latest solutions ... the early identification of cancer at the Radiological ... in Chicago from November ... showcase recent product advances including iReveal®, an automated ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... EMIGSVILLE, PA (PRWEB) , ... November 30, 2015 ... ... (CCMS) software provider, has verified that their Vasont Universal Integrator (VUI) extension unites ... handle creating, editing, and managing content as a continuous process with the latest ...
(Date:11/30/2015)... ... 30, 2015 , ... Healthjump, Inc. announced that it has ... consulting, development and support company. The purchase will expand the capability to serve ... extend the services currently provided by Healthjump. , Through this purchase, ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability to present dynamic ... schools of the future. To reach an audience of key visionaries and reformers ... in Chicago, organized by the American Medical Association. , AMA President Steven ...
Breaking Medicine News(10 mins):